Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Intelligent Bio Solutions Inc. filed a current report highlighting two main updates. The company furnished an investor presentation made available on April 20, 2026, describing its business and operations and accessible through the Investors section of its website.

The company also reported that its total outstanding common shares were 2,176,848 as of April 20, 2026. This outstanding share count reflects issuances tied to exercised warrants and sales of common stock under a previously disclosed at-the-market offering agreement since a prior filing on March 23, 2026.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Shares outstanding: 2,176,848 shares

1 metrics

Shares outstanding 2,176,848 shares Common stock outstanding as of April 20, 2026

Key Terms

Regulation FD, At The Market Offering Agreement, emerging growth company, warrants, +1 more

5 terms

Regulation FD regulatory

"Pursuant to Regulation FD, Intelligent Bio Solutions Inc. hereby furnishes the presentation"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

At The Market Offering Agreement financial

"sale of Common Stock by the Company pursuant to the previously disclosed At The Market Offering Agreement"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

warrants financial

"the exercise of previously issued outstanding warrants to purchase Common Stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Understanding 8-K Material Events →

04/20/2026 - 08:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 20, 2026

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State of

Incorporation)

(Commission

File Number)

(IRS employer

identification no.)

135 West, 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 790-5756

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Investor Presentation

Pursuant to Regulation FD, Intelligent Bio Solutions Inc. (the “Company”) hereby furnishes the presentation (the “Presentation”) that the Company made available to investors on April 20, 2026, relating to the Company’s business and operations. The Presentation can be accessed by visiting the Investors section of the Company’s website: www.ibs.inc.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 8.01 Other Events

Shares Outstanding Update

Following the issuance of Company common stock, $0.01 par value per share (“Common Stock”), in connection with (a) the exercise of previously issued outstanding warrants to purchase Common Stock, and (b) the sale of Common Stock by the Company pursuant to the previously disclosed At The Market Offering Agreement, dated September 18, 2024, between the Company and Ladenburg Thalmann & Co. Inc., in each case since the filing of the Company’s Current Report on Form 8-K on March 23, 2026, the total number of outstanding shares of Company Common Stock as of April 20, 2026, was 2,176,848 shares.

Item 9.01 Financial Statements and Exhibits.

No.		Description
99.1		Presentation made available on April 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 20, 2026
	INTELLIGENT BIO SOLUTIONS INC.

	By:	/s/ Spiro Sakiris
	Name:	Spiro Sakiris
	Title:	Chief Financial Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Intelligent Bio Solutions Inc. (INBS) disclose in this 8-K?

Intelligent Bio Solutions Inc. disclosed that it furnished an updated investor presentation and provided a revised outstanding share count. The presentation outlines its business and operations, while the share update reflects recent warrant exercises and at-the-market stock sales.

How many Intelligent Bio Solutions (INBS) shares were outstanding on April 20, 2026?

The company reported that 2,176,848 shares of common stock were outstanding as of April 20, 2026. This figure includes shares issued from exercised warrants and shares sold under an at-the-market offering agreement since a prior March 23, 2026 filing.

What is the investor presentation mentioned by Intelligent Bio Solutions (INBS)?

The investor presentation is a slide deck furnished under Regulation FD on April 20, 2026. It provides information on Intelligent Bio Solutions’ business and operations and can be accessed through the Investors section of the company’s website as Exhibit 99.1.

How were new Intelligent Bio Solutions (INBS) shares issued before April 20, 2026?

The company states that additional common shares were issued through the exercise of previously issued outstanding warrants and through sales of common stock under a previously disclosed at-the-market offering agreement with Ladenburg Thalmann & Co. Inc., following a March 23, 2026 filing.

Does the Intelligent Bio Solutions (INBS) investor presentation count as filed financial information?

The company specifies that the investor presentation furnished under Item 7.01 is not deemed filed under the Exchange Act. It is also not incorporated into other securities filings unless specifically identified as incorporated by reference in those documents.

What exhibits were included with Intelligent Bio Solutions’ (INBS) 8-K?

The company attached two exhibits: Exhibit 99.1, which is the investor presentation made available on April 20, 2026, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document associated with the report.

Filing Exhibits & Attachments

30 documents